Skip to main content

Market Overview

Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer


The FDA has issued a complete response letter (CRL) for Athenex Inc’s (NASDAQ: ATNX) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer.

  • The CRL indicated concern about an increase in neutropenia-related sequelae observed on the oral paclitaxel arm compared with the IV paclitaxel arm.
  • The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate at week 19 conducted by blinded independent central review (BICR).
  • It suggested that the BICR was influenced.
  • The agency recommended that the company conduct a new trial and adopt additional risk mitigation strategies to improve toxicity.
  • Athenex plans to request a meeting with the FDA to discuss the agency’s response.
  • Price Action: ATNX shares dropped 21% at $9.49 in the premarket before the trading halted. It will resume at 7:35 a.m. ET.

Related Articles (ATNX)

View Comments and Join the Discussion!

Posted-In: breast cancerBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at